Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant v. Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Delaware federal court jury affirms that Medtronic Driver and S7 coronary stents infringe Guidant's Lau patents, and that the patents are valid. The move is in-line with a Jan. 5 ruling and overturns a subsequent reversal (1"The Gray Sheet" Jan. 10, 2005, p. 3). Medtronic says its next step will be to pursue an unenforceability claim for "inequitable conduct," and that the current findings do not affect U.S. sales of the devices...

You may also be interested in...



Medtronic Stent Patent Ruling Makes DES Vulnerable; Will Guidant Cut Deal?

Medtronic will appeal a Delaware federal court patent infringement ruling against its Driver and S7 coronary stents and challenge the validity of Guidant's Lau patent, the firm says

99 Days Until MDR: Time Is Running Out For Medtech As Risky, Volatile Future Looms

The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.
UsernamePublicRestriction

Register

MT021639

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel